Rhabdomyosarcoma clinical trials

Explore recruiting rhabdomyosarcoma clinical trials.

Recruiting rhabdomyosarcoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Rhabdomyosarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

Netherlands, Portugal, Italy, Sweden, Norway, Austria +10 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

Sweden, France, Germany, Spain, Belgium, Czechia +6 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies

Germany, Italy, France, Spain, Netherlands, Denmark +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors

Spain, Germany, France, Denmark, Hungary, Czechia +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

COTESARC : A multicentre, open-label, Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Rhabdomyosarcoma trials by city

Rhabdomyosarcoma in Toronto Rhabdomyosarcoma in Vancouver Rhabdomyosarcoma in Montreal Rhabdomyosarcoma in Calgary Rhabdomyosarcoma in Edmonton Rhabdomyosarcoma in Ottawa Rhabdomyosarcoma in Winnipeg Rhabdomyosarcoma in Quebec City Rhabdomyosarcoma in Hamilton Rhabdomyosarcoma in Kitchener Rhabdomyosarcoma in London Rhabdomyosarcoma in Halifax Rhabdomyosarcoma in New York Rhabdomyosarcoma in Los Angeles Rhabdomyosarcoma in Chicago Rhabdomyosarcoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease